FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128889351> ?p ?o ?g. }

• W3128889351 abstract "Background: Toll-like receptor 4 (TLR4) initiates both innate and adaptive immune responses, which plays an important protective role in self-defense mechanisms. Excessive or inappropriate TLR4 activation causes the development of many autoimmune diseases. Dihydropyrimidinone derivatives are medicinally important molecules with diverse pharmacological activities, including anti-inflammatory activity. The present study focused on novel synthesized 3,4-dihydropyrimidinone derivatives and evaluated their inhibitory effects on TLR4. Methods: A series of 3,4-dihydropyrimidinone derivatives were recently synthesized and evaluated for their TLR4 inhibition activities and cytotoxic on HEK-Blue TM hTLR4 cells with the help of QUANTI-Blue assay and MTS assay. Selected compound 3 was analyzed for its molecular docking with TLR4 by using Autodock vina 1.1.2. Its effect on the TLR4 pathway related cytokines was also evaluated in THP-1 cells and human peripheral blood mononuclear cells by using real-time PCR, ELISA and western blot. Results: Five compounds were synthesized and characterized for effectiveness based on 3,4-dihydropyrimidinone. Compound 3 was found to be the potent hybrid among the synthesized compounds, with high TLR4 inhibition activities and low cytotoxic activities against HEK-Blue TM hTLR4 cells. Molecular docking analysis showed that two hydrogen bonds between compound 3 and residues Asp209(TLR4) and Asp99(MD-2) mainly contribute to the TLR4 inhibition. In addition, compound 3 suppressed LPS-induced of the mRNA expression of TLR4, IP-10, TNF-α, IL-6, IL-12A, and IL-12B, the protein expression of pIRF3 and pNFκB and the secretion of IP-10, TNF-α in THP-1 cell line. Compound 3 also inhibited LPS-induced expression of TNF-α, IL-6, and IL-1β but increased IP-10 at mRNA levels in human peripheral blood mononuclear cells. Conclusion: Our study reveals compound 3, a novel 3,4-dihydropyrimidinone derivative, is a potential TLR4 antagonist, which opens up new research avenues for the development of promising therapeutic agents for inflammatory and autoimmune diseases." @default.
• W3128889351 created "2021-02-15" @default.
• W3128889351 creator A5016928831 @default.
• W3128889351 creator A5027519026 @default.
• W3128889351 creator A5028074515 @default.
• W3128889351 creator A5064509388 @default.
• W3128889351 creator A5077074056 @default.
• W3128889351 date "2021-02-01" @default.
• W3128889351 modified "2023-10-12" @default.
• W3128889351 title "Specific TLR4 Blocking Effect of a Novel 3,4-Dihydropyrimidinone Derivative" @default.
• W3128889351 cites W1990006153 @default.
• W3128889351 cites W1993792235 @default.
• W3128889351 cites W2003957345 @default.
• W3128889351 cites W2010993726 @default.
• W3128889351 cites W2015415445 @default.
• W3128889351 cites W2033023829 @default.
• W3128889351 cites W2037756277 @default.
• W3128889351 cites W2037894162 @default.
• W3128889351 cites W2047453870 @default.
• W3128889351 cites W2053189438 @default.
• W3128889351 cites W2056812842 @default.
• W3128889351 cites W2063155121 @default.
• W3128889351 cites W2068303069 @default.
• W3128889351 cites W2075713060 @default.
• W3128889351 cites W2088360104 @default.
• W3128889351 cites W2094650342 @default.
• W3128889351 cites W2105668062 @default.
• W3128889351 cites W2113769407 @default.
• W3128889351 cites W2128533924 @default.
• W3128889351 cites W2134967712 @default.
• W3128889351 cites W2136817329 @default.
• W3128889351 cites W2158591358 @default.
• W3128889351 cites W2161681729 @default.
• W3128889351 cites W2167742884 @default.
• W3128889351 cites W2292460510 @default.
• W3128889351 cites W2320905063 @default.
• W3128889351 cites W2397385450 @default.
• W3128889351 cites W2517922594 @default.
• W3128889351 cites W2527894900 @default.
• W3128889351 cites W2605479380 @default.
• W3128889351 cites W2737868829 @default.
• W3128889351 cites W2752232413 @default.
• W3128889351 cites W2760109000 @default.
• W3128889351 cites W2765167446 @default.
• W3128889351 cites W2787008890 @default.
• W3128889351 cites W2799951009 @default.
• W3128889351 cites W2803489825 @default.
• W3128889351 cites W2805170286 @default.
• W3128889351 cites W2890602632 @default.
• W3128889351 cites W2900611152 @default.
• W3128889351 cites W2900743281 @default.
• W3128889351 cites W2944569053 @default.
• W3128889351 cites W2952853804 @default.
• W3128889351 cites W2998644011 @default.
• W3128889351 cites W3004722355 @default.
• W3128889351 cites W4249383371 @default.
• W3128889351 doi "https://doi.org/10.3389/fphar.2020.624059" @default.
• W3128889351 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7882735" @default.
• W3128889351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33597886" @default.
• W3128889351 hasPublicationYear "2021" @default.
• W3128889351 type Work @default.
• W3128889351 sameAs 3128889351 @default.
• W3128889351 citedByCount "7" @default.
• W3128889351 countsByYear W31288893512021 @default.
• W3128889351 countsByYear W31288893512022 @default.
• W3128889351 countsByYear W31288893512023 @default.
• W3128889351 crossrefType "journal-article" @default.
• W3128889351 hasAuthorship W3128889351A5016928831 @default.
• W3128889351 hasAuthorship W3128889351A5027519026 @default.
• W3128889351 hasAuthorship W3128889351A5028074515 @default.
• W3128889351 hasAuthorship W3128889351A5064509388 @default.
• W3128889351 hasAuthorship W3128889351A5077074056 @default.
• W3128889351 hasBestOaLocation W31288893511 @default.
• W3128889351 hasConcept C104317684 @default.
• W3128889351 hasConcept C137061746 @default.
• W3128889351 hasConcept C159110408 @default.
• W3128889351 hasConcept C170493617 @default.
• W3128889351 hasConcept C185592680 @default.
• W3128889351 hasConcept C202751555 @default.
• W3128889351 hasConcept C2776070231 @default.
• W3128889351 hasConcept C2776415932 @default.
• W3128889351 hasConcept C41685203 @default.
• W3128889351 hasConcept C55493867 @default.
• W3128889351 hasConcept C71924100 @default.
• W3128889351 hasConcept C86803240 @default.
• W3128889351 hasConcept C98274493 @default.
• W3128889351 hasConceptScore W3128889351C104317684 @default.
• W3128889351 hasConceptScore W3128889351C137061746 @default.
• W3128889351 hasConceptScore W3128889351C159110408 @default.
• W3128889351 hasConceptScore W3128889351C170493617 @default.
• W3128889351 hasConceptScore W3128889351C185592680 @default.
• W3128889351 hasConceptScore W3128889351C202751555 @default.
• W3128889351 hasConceptScore W3128889351C2776070231 @default.
• W3128889351 hasConceptScore W3128889351C2776415932 @default.
• W3128889351 hasConceptScore W3128889351C41685203 @default.
• W3128889351 hasConceptScore W3128889351C55493867 @default.
• W3128889351 hasConceptScore W3128889351C71924100 @default.
• W3128889351 hasConceptScore W3128889351C86803240 @default.
• W3128889351 hasConceptScore W3128889351C98274493 @default.
• W3128889351 hasFunder F4320321001 @default.

• next